Skip to main content
. 2017 Nov 6;19(Suppl 5):v1–v88. doi: 10.1093/neuonc/nox158

Table 22.

One-, Two-, Five-, and Ten-Year Relative Survival Ratesa,b for Selected Malignant Brain and Other Central Nervous System Tumors by Age-Group, SEER 18 Registries, 2000-2014c

Histology Age-Group (years) N d 1-Year 2-Year 5-Year 10-Year
% 95% CI % 95% CI % 95% CI % 95% CI
Pilocytic astrocytoma 0-19 2,821 98.7 98.1-99.0 98.2 97.6-98.7 96.7 95.8-97.3 95.7 94.6-96.6
20-44 775 96.6 95.0-97.7 94.5 92.6-96.0 91.7 89.2-93.6 86.3 82.7-89.3
45-54 149 95.4 90.0-97.9 86.4 79.0-91.3 78.4 69.5-85.1 75.5 65.6-82.9
55-64 85 96.0 87.6-98.8 90.4 80.4-95.4 82.6 71.0-89.9 76.6 61.1-86.6
65-74 -- -- -- -- -- -- -- -- --
75+ -- -- -- -- -- -- -- -- --
Diffuse astrocytoma 0-19 928 93.2 91.3-94.7 87.8 85.3-89.8 83.6 80.8-86.0 81.7 78.7-84.3
20-44 2,194 93.3 92.1-94.3 87.0 85.4-88.4 68.5 66.3-70.7 49.5 46.7-52.2
45-54 992 77.0 74.2-79.6 62.6 59.4-65.7 44.3 40.8-47.7 31.8 28.0-35.7
55-64 885 56.7 53.3-60.0 37.0 33.6-40.4 22.3 19.2-25.5 14.3 11.0-18.1
65-74 640 42.8 38.8-46.7 26.8 23.2-30.6 11.9 12.6-19.3 11.9 8.5-15.8
75+ 535 26.2 22.4-30.2 13.8 10.7-17.3 6.9 4.3-10.3 1.4 0.2-6.2
Anaplastic astrocytoma 0-19 321 69.0 63.5-73.9 40.7 35.0-46.4 28.2 22.8-33.8 20.1 14.7-26.1
20-44 1,404 89.4 87.6-91.0 75.4 72.8-77.7 55.1 51.9-58.1 39.7 36.1-43.3
45-54 734 74.1 70.7-77.2 51.9 48.0-55.7 31.0 27.2-35.0 22.0 17.9-26.4
55-64 734 54.4 50.6-58.0 30.2 26.7-33.7 13.2 10.4-16.3 6.1 3.7-9.4
65-74 571 37.0 32.9-41.0 18.0 14.8-21.6 8.0 5.5-11.0 4.9 2.8-7.8
75+ 413 18.7 14.9-22.8 9.4 6.5-12.9 1.2 0.3-3.8 0.7 0.1-3.2
Glioblastoma 0-19 482 58.8 54.2-63.1 34.3 29.8-38.8 17.7 13.9-21.8 13.0 9.3-17.3
20-44 3,054 69.9 68.2-71.6 40.9 39.1-42.7 19.0 17.4-20.6 11.0 9.6-12.6
45-54 5,938 57.6 56.3-58.9 25.6 24.4-26.8 7.7 6.9-8.5 4.0 3.3-4.8
55-64 9,280 46.1 45.1-47.1 18.0 17.2-18.8 4.6 4.1-5.1 1.9 1.5-2.4
65-74 8,354 29.3 28.3-30.3 29.3 28.3-30.3 2.4 2.0-2.9 1.0 0.6-1.5
75+ 6,843 12.2 11.4-13.1 3.7 3.3-4.3 1.0 0.7-1.4 -- --
Oligodendroglioma 0-19 229 96.4 92.9-98.2 94.5 90.5-96.9 90.5 85.4-93.8 88.6 83.0-92.4
20-44 1,636 98.7 97.9-99.2 96.4 95.3-97.3 87.9 86.0-89.6 70.6 67.4-73.5
45-54 734 94.6 92.6-96.1 90.2 87.6-92.3 81.0 77.5-84.0 65.2 60.0-69.8
55-64 403 88.9 85.1-91.7 78.9 74.2-82.9 69.1 63.4-74.1 53.2 45.4-60.4
65-74 170 80.7 73.4-86.2 74.1 65.9-80.6 54.6 44.9-63.3 37.0 25.2-48.8
75+ 90 61.8 49.8-71.7 50.5 38.1-61.7 38.3 25.0-51.5 13.1 4.8-25.7
Anaplastic oligodendroglioma 0-19 -- -- -- -- -- -- -- -- --
20-44 544 94.4 92.0-96.1 85.2 81.7-88.1 71.2 66.7-75.2 55.2 49.6-60.5
45-54 351 89.3 85.4-92.2 77.9 72.8-82.1 62.8 56.7-68.3 45.2 37.9-52.2
55-64 288 77.9 72.5-82.5 62.4 56.1-68.0 45.2 38.5-51.6 31.8 24.4-39.4
65-74 129 55.1 45.8-63.4 35.5 26.8-44.3 19.1 11.5-28.2 13.6 6.6-23.2
75+ -- -- -- -- -- -- -- -- --
Ependymal tumors 0-19 821 95.0 93.2-96.3 88.0 85.5-90.2 75.8 72.3-78.9 66.9 62.6-70.7
20-44 912 97.4 96.0-98.3 95.5 93.8-96.8 91.6 89.3-93.5 88.8 85.7-91.3
45-54 533 95.5 93.2-97.1 93.2 90.4-95.2 89.7 86.1-92.4 87.8 83.4-91.1
55-64 386 93.0 89.7-95.3 89.7 85.7-92.6 87.1 82.2-90.8 84.3 76.7-89.6
65-74 184 88.6 82.4-92.8 82.8 75.3-88.2 81.0 72.9-86.9 70.2 55.5-80.8
75+ 91 67.2 55.4-76.5 63.6 50.7-73.9 51.0 35.4-64.6 32.3 13.3-53.1
Oligoastrocytic tumors 0-19 120 94.9 88.9-97.7 89.6 82.3-94.0 83.6 74.9-89.4 78.1 68.0-85.3
20-44 1,152 96.8 95.5-97.7 90.9 88.9-92.5 73.4 71.4-76.3 55.5 51.4-59.4
45-54 433 89.4 85.9-92.0 78.3 73.8-82.1 65.8 60.5-70.6 48.2 41.0-55.0
55-64 248 74.5 68.3-79.7 52.1 45.2-58.5 35.9 29.0-43.0 30.0 21.9-38.5
65-74 140 66.6 57.7-74.1 47.2 38.0-55.9 25.3 17.2-34.2 15.9 8.2-25.9
75+ -- -- -- -- -- -- -- -- --
Glioma malignant, NOS 0-19 1,814 77.8 75.8-79.7 67.3 65.0-69.5 64.1 61.7-66.4 62.4 59.9-64.8
20-44 968 88.3 86.0-90.2 79.8 77.0-82.4 69.5 66.1-72.6 55.8 51.3-60.1
45-54 481 74.9 70.6-78.6 60.4 55.6-64.8 50.6 45.5-55.4 41.2 35.4-46.9
55-64 409 57.6 52.4-62.4 43.1 37.9-48.3 33.3 28.0-38.6 28.3 22.2-34.5
65-74 396 38.6 33.6-43.5 24.9 20.5-29.6 17.2 13.0-21.8 14.2 9.7-19.6
75+ 738 17.6 14.8-20.6 13.2 10.6-16.1 9.7 7.0-12.9 8.0 4.6-12.6
Neuronal and mixed neuronal-glial tumors 0-19 73 94.2 85.1-97.8 89.2 78.6-94.8 85.8 74.2-92.4 85.8 74.2-92.4
20-44 148 95.3 90.2-97.8 89.5 82.9-93.6 77.8 69.2-84.2 62.7 51.1-72.2
45-54 131 94.1 88.0-97.2 90.2 83.0-94.5 84.3 75.6-90.1 74.6 60.5-84.3
55-64 114 91.3 83.6-95.5 81.9 72.0-88.6 68.7 56.5-78.1 50.6 34.3-64.8
65-74 63 84.8 71.9-92.1 82.8 68.6-91.0 80.0 64.3-89.4 -- --
75+ -- -- -- -- -- -- -- -- --
Embryonal tumors 0-19 2,175 81.1 79.3-82.7 71.2 69.2-73.1 62.3 60.0-64.4 56.0 53.5-58.4
20-44 595 86.7 83.6-89.2 79.5 75.8-82.7 66.7 62.3-70.8 59.1 54.0-63.8
45-54 89 82.8 72.8-89.4 70.1 58.8-79.0 57.5 44.7-68.4 38.7 23.7-53.5
55-64 -- -- -- -- -- -- -- -- --
65-74 -- -- -- -- -- -- -- -- --
75+ -- -- -- -- -- -- -- -- --
Meningioma 0-19 -- -- -- -- -- -- -- -- --
20-44 143 95.2 89.9-97.7 94.6 89.1-97.4 87.8 80.4-92.5 78.0 68.6-85.0
45-54 186 92.8 87.8-95.8 85.2 78.9-89.8 76.7 69.1-82.7 69.7 60.8-77.0
55-64 274 88.7 84.0-92.1 80.9 75.3-85.4 68.6 61.8-74.5 59.5 51.4-66.6
65-74 253 80.2 74.3-84.9 70.1 63.3-75.9 53.5 45.5-60.8 48.9 38.6-58.3
75+ 300 62.9 56.5-68.7 56.1 49.0-62.5 48.8 40.0-56.9 39.5 27.3-51.4
Lymphoma 0-19 68 83.7 72.5-90.7 76.1 63.9-84.6 71.2 58.5-80.6 66.5 52.8-77.1
20-44 784 56.7 53.1-60.2 50.7 47.1-54.3 44.4 40.7-48.1 39.2 35.1-43.2
45-54 737 62.3 58.6-65.7 53.4 49.6-57.1 41.6 37.6-45.5 31.5 27.2-35.8
55-64 1,045 62.3 59.2-65.3 53.4 50.1-56.5 38.7 35.3-42.1 28.7 24.8-32.7
65-74 1,183 50.3 47.3-53.2 41.3 38.2-44.3 27.6 24.5-30.7 17.4 13.9-21.3
75+ 1,001 33.6 30.5-36.7 24.0 16.4-22.2 15.4 12.5-18.6 12.0 8.0-17.0
TOTAL: All Brain and Other Nervous System e 0-19 11,196 87.1 86.5-87.7 79.9 79.1-80.6 73.9 73.0-74.8 70.4 69.4-71.3
20-44 15,305 86.6 86.0-87.1 75.9 75.1-76.6 61.9 61.0-62.8 49.8 48.8-50.8
45-54 11,950 69.5 68.6-70.3 48.3 47.3-49.2 33.5 32.6-34.5 26.4 25.3-27.4
55-64 14,645 53.9 53.1-54.7 31.2 30.4-32.0 18.4 17.6-19.1 13.7 13.0-14.5
65-74 12,676 36.6 35.7-37.4 20.5 19.7-21.2 11.3 10.7-12.0 8.1 7.4-8.9
75+ 11,682 18.0 17.3-18.8 10.3 9.7-10.9 6.2 5.6-6.8 4.2 3.5-5.0

aThe cohort analysis of survival rates was utilized for calculating the survival estimates presented in this table. Long-term cohort-based survival estimates reflect the survival experience of individuals diagnosed over the time period, and they may not necessarily reflect the long-term survival outlook of newly diagnosed cases.

bRates are an estimate of the percentage of patients alive at one, two, five, and ten years, respectively. Rates were not presented for categories with 50 or less cases and were suppressed for rates where less than 16 cases were surviving within a category.

cEstimated by CBTRUS using Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2015 Sub (2000-2014) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2015 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2017, based on the November 2016 submission.

dTotal number of case that occurred within the SEER registries between 2000 and 2014.

eTotal includes histologies not listed in this table.